Short communication

MYRICETIN BLOCKS LIPOTEICHOIC ACID-INDUCED COX-2 EXPRESSION IN HUMAN GINGIVAL FIBROBLASTS

GLORIA GUTIÉRREZ-VENEGAS*, OSCAR ALONSO LUNA, JUAN ANTONIO ARREGUÍN-CANO and CRISTINA HERNÁNDEZ-BERMÚDEZ
Laboratorio de Bioquímica, División de Estudios de Posgrado e Investigación, Facultad de Odontología, Universidad Nacional Autónoma de México, Ciudad de México, México

Abstract: Periodontitis is an infectious disease caused by microorganisms present in dental bacterial plaque. Lipoteichoic acid (LTA) is a component of the external membrane of Gram-positive bacteria. It causes septic shock. Ingested flavonoids have been reported to directly affect the regulation of cyclooxygenase-2 (COX-2) expression induced by bacterial toxins. In this study, we examined the effects of four flavonoids (luteolin, fisetin, morin and myricetin) on the activation of ERK1/2, p38 and AKT, and on the synthesis of COX-2 in human gingival fibroblasts treated with LTA from Streptococcus sanguinis. We found that luteolin and myricetin blocked AKT and p38 activation and that myricetin blocked LTA-induced COX-2 expression. The results of our study are important for elucidating the mechanism of action of flavonoid regulation of inflammatory responses.

Keywords: Periodontitis, Fisetin, Morin, Myricetin, Luteolin, Human gingival fibroblasts, Lipoteichoic acid, Cyclooxygenase

INTRODUCTION

Periodontitis is a progressive disease that affects the dentition-supporting tissues, including the gums, periodontal ligaments and alveolar bone [1–3]. The principal result of advanced periodontitis is tooth loss. Periodontitis is an infectious disease caused by an accumulation of certain microorganisms that live

* Author for correspondence. Email: gloria@fo.odonto.unam.mx

Abbreviations used: COX-2 – cyclooxygenase-2; HGF – human gingival fibroblasts; LTA – lipoteichoic acid; MAPK – mitogen-activated protein kinases; PAMPS – pathogen-associated molecular patterns, SDS – sodium dodecyl sulfate; TLR – Toll-like receptors
in dental bacterial plaque. The response of the host to these oral pathogens is a key determinant in the development of periodontitis [4, 5].

Human gingival fibroblasts (HGFs), the predominant cell type in periodontal connective tissue, form a framework that anchors the teeth. They play an active role in the host defense response. Exposing gingival fibroblasts to pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide, lipoteichoic acid or peptidoglycan, promotes the expression of inflammatory cytokines such as the interleukins IL-1β, IL-6 and IL-8, and the enzyme cyclooxygenase [6–11].

HGFs are thought to play an important role in promoting inflammatory responses.

Toll-like receptors (TLRs) play a significant role in PAMP recognition and the induction of molecules that act primarily to reduce the action of pathogens, but also favor the production of pro-inflammatory molecules and the development of chronic periodontitis [12–15]. Lipoteichoic acid (LTA) is a pathogen-associated molecular pattern obtained from Gram-positive bacteria. It associates with TLR-2 and is responsible for septic shock via its promotion of the expression of pro-inflammatory cytokines. The premise that periodontal pathogens or their components are associated with the development of periodontal disease has spurred extensive research into ways to control the disease by regulating activated intracellular signaling pathways [16–19].

There is growing evidence that plant-derived foods and beverages contribute to the healthy development and status of blood vessels and connective tissues. In particular, the large family of plant-derived polyphenols has potential benefits, including putative positive effects on obesity and cardiovascular diseases. Fisetin (3,3’4’,7-tetrahydroxyflavone) is a polyphenolic flavonoid found in various fruits and vegetables, including strawberries, mangoes, apples, grapes, cucumbers and onions [20, 21]. Fisetin has been reported to show antioxidant [22], anti-tumor [23], anti-diabetic [24], anti-aging [25] and neuroprotective [25] properties. Morin (3,2’,4’,5,7-pentahydroxyflavone) and myricetin (3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromone) are structurally related flavonols, a common flavonoid type. Morin is abundant in fig and almond shells. Like fisetin, it has been reported to have anti-tumor [26], anti-oxidant [27] and anti-inflammatory [28] properties. Myricetin, the predominant flavonoid in grapes, blackberries, onions and red wine [29], has been shown to inhibit COX-2 synthesis, AP-1 activation and cyclin expression in epidermal cells treated with phorbol esters [31–35].

Among its other functions, the carotenoid luteolin (3’,4’,5,7-tetrahydroxyflavone) protects the endothelium from superoxide anions and high glucose levels [36]. It has inhibitory effects on tumor growth [37] and can reduce inflammation [38, 39]. In previous studies, we showed that luteolin blocked AKT-mediated nitric oxide production in gingival fibroblasts treated with lipopolysaccharide. Here, we sought to evaluate the effects of morin, myricetin, fisetin and luteolin on the actions of LTA in HGFs.
MATERIALS AND METHODS

Compounds
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum and SuperScript One-Step RT-PCR reagents were purchased from Invitrogen. Luteolin, morin, myricetin, fisetin, phenylmethylsulfonyl fluoride, sodium dodecyl sulfate, ethylenediaminetetraacetic acid (EDTA), tetrazolium salt, and LTA purified from Streptococcus sanguinis were obtained from Sigma Aldrich. All four flavonoids were dissolved in ethanol. Antibodies agonist p38, AKT, γ-tubulin, p50, phospho-ERK (Thr 202/Tyr204), phospho-p38 (Tyr 182), phospho-AKT (within the C-terminal Ser 473) and phospho-AKT (Thr 308), and luminol reagent were purchased from Santa Cruz Biotechnology.

Cell culture
HGFs were obtained from healthy tissue samples from patients at the Exodontia Clinic after informed consent was obtained (FBQ-LIFO-001 ISO 9001:2008). The Ethical Committee of the Universidad Nacional Autónoma de México approved the protocol for our study. Gingival tissue was isolated at the cement–enamel junction of the extracted tooth using a surgical blade. The harvested tissue was rinsed several times in DMEM containing antibiotics (100 U/ml penicillin, 125 μg/ml streptomycin and 5 μg/ml amphotericin). The tissue was cut into small pieces and cultured with a medium containing 10% fetal bovine serum. When the cells that grew from the explants had reached confluence, they were detached using 0.025% (w/v) trypsin in PBS for 10 min and subcultured in flasks. The cells that remained attached to the bottom of the flask were discarded in order to avoid contamination with epithelial cells, which are not as easily detached as fibroblasts. The HGFs were cultured in a humidified atmosphere of 5% CO₂ at 37°C. The cell cultures used in all of the experiments were between passages 5 and 10 [40].

Western blot analysis
At the end of treatment, the cell culture medium was aspirated and the cells were detached in PBS with 1 mM Na₂VO₃ by scraping. Detached cells were transferred to fresh microcentrifuge tubes and centrifuged at 5000 rpm and 4°C for 10 min. The cell pellets were then lysed in 10 μl lysis buffer consisting of 0.05 M Tris-HCl (pH 7.4), 0.15 M NaCl, 1% Nonidet P-40, 0.5 M phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml leupeptin, 0.4 mM sodium orthovanadate, 10 mM sodium fluoride and 10 mM sodium pyrophosphate (all obtained from Sigma Chemical Co.). The protein concentrations were determined using the standard Bradford assay. For western blotting, an equal amount of protein from each sample was loaded onto SDS-PAGE gel and electrotransferred onto PVDF membranes (Invitrogen Life Technologies). These membranes were then blocked with 5% (w/v) nonfat milk in TBST consisting of 10 mM Tris, 150 mM NaCl and 0.1% (v/v) Tween 20 (pH 7.5) for 1 h at room temperature and incubated with primary antibodies overnight at 4°C. Secondary
antibody incubation was at room temperature for 2 h (Santa Cruz Biotechnology). Chemiluminescence ECL (Amersham) was used to detect immunoreactive protein signals. Protein signals were then visualized on films and scanned and quantified using the Digi-Doc software. For re-probing, PVDF membranes were stripped with 0.2 M NaOH for 10 min before blocking with another primary antibody. The expression of the protein of interest was determined relative to the basal level.

**RT-PCR analysis of inducible COX-2**

Total cellular RNA was isolated from human gingival fibroblasts using the method described by Chomczynski and Sacchi [41]. Total cell RNA (1 μg) was reverse transcribed using the One Step RT-PCR kit (Invitrogen). PCR was performed using the oligonucleotides 5'-TTCAAATGAGATTGTGGGAAAATTGCT-3' (coding sense) and 5'-AGATCATCTCTCTGAGTATCTT-3' (anticoding sense) derived from the COX-2 gene and 5'-AGATCCACAACGGATACATT-3' (anticoding sense) derived from the glyceraldehyde-3-phosphate dehydrogenase (GADPH) gene [42]. PCR amplification conditions included denaturing at 94°C for 1 min, annealing at 55°C for 1 min and extension at 72°C for 1.5 min; PCR was carried out for 35 cycles. Fragment identity was characterized based on the apparent fragment size using ethidium bromide-stained agarose gels. Five independent experiments were performed for each treatment. Data were analyzed with LabsWorks 4.0 commercial software. Each densitometric value was expressed as mean ± S.D.

**Statistical analysis**

Each experiment was repeated at least three times. The quantified results are presented as the means ± SD. Significant differences were determined using factorial analysis of variance (ANOVA). p < 0.05 was considered significant difference.

Fig. 1. LTA treatment promotes the phosphorylation of ERK1/2 and p38 in HGFs. The fibroblasts were incubated with LTA (10 μg/ml) for the time intervals indicated. The cell lysates were separated by electrophoresis in SDS-PAGE gels, then transferred to PVDF membranes and immunoblotted with (A) anti-phosphorylated ERK1/2 and (B) anti-phosphorylated p38. The membranes were then stripped and incubated with anti-ERK1/2 and anti-p38. The results shown are representative of three separate experiments. SEMs were obtained by densitometry. *p < 0.05; significantly different from the values for cells treated with LTA only.
RESULTS

LTA from *S. sanguinis* promotes MAPK activation

When HGF cultures were exposed to LTA (10 µg/ml), a time-dependent increase occurred in the phosphorylation patterns of the MAPKs (mitogen-activated protein kinases), ERK1/2 and p38. The maximum LTA effects were observed 15 min after the LTA treatment (Fig. 1). Densitometric analysis showed that treatment with LTA promoted phosphorylation of ERK1/2 (Fig. 1A) and p38 (Fig. 1B) to levels that were twofold higher than the basal activity levels.

LTA from *S. sanguinis* induces the activation of AKT and degradation of IκB

We studied the effects of LTA on the activation of AKT, which is a serine/threonine kinase that plays a key role in diverse cellular events, such as

![Graphs showing phosphorylation of AKT and degradation of IκB](image)

Fig. 2. LTA treatment promotes phosphorylation of AKT and degradation of IκB in HGFs. The fibroblasts were incubated with LTA (10 µg/ml) for the time intervals indicated. The cell lysates were separated by electrophoresis in SDS-PAGE gels, transferred to Hybond-P membranes and immunoblotted with (A) – anti-phosphorylated-AKT (Ser 473), (B) – anti-phosphorylated-AKT (Ser 308) and (C) – anti-IκB antibodies. The membranes were stripped and incubated with AKT or α-tubulin. The results shown are representative of three separate experiments. SEMs were obtained by densitometry. *p < 0.05; significantly different from the values for cells treated with LTA only.
apoptosis and cell proliferation. We found an increase in AKT phosphorylation at serine 308 for 15 min after the exposure to LTA. Maximal phosphorylation was detected after 30 min and phosphorylation levels returned to basal levels by 120 min after LTA treatment (Fig. 2A). Similar results were obtained with AKT phosphorylation at serine 473 (Fig. 2B). We then studied the effects of LTA on IκB. LTA promoted the degradation of IκB 15 min after initiation of the treatment. This degradation response was sustained for up to 60 min and returned to basal levels by 120 min (Fig. 2C).

**Flavonoids inhibit LTA-induced MAPK phosphorylation**
In order to evaluate the effects of the flavonoids on LTA-induced ERK1/2 phosphorylation, we incubated cells with luteolin, fisetin, morin and myricetin (10 μM). All of the tested flavonoids blocked ERK1/2 and p38 activation after

![Flavonoids inhibit LTA-induced phosphorylation of ERK1/2, p38 and AKT in HGFs. The cells were incubated with the flavonoids (10 μM) for 30 min and then treated with LTA (10 μg/ml) for 15 min. Cell lysates were separated in SDS-PAGE gels, transferred to Hybond-P membranes, and incubated with anti-phosphorylated ERK1/2 (A), anti-phosphorylated-p38 (B) and anti-phosphorylated-AKT (C) antibodies. The results are representative of three separate experiments. SEMs were obtained by densitometry. *p < 0.05; significantly different from the values for cells treated with LTA only.](image-url)
15 min of treatment. Morin and myricetin treatment significantly reduced ERK1/2 phosphorylation (Fig. 3A). We found that luteolin, fisetin and myricetin inhibited p38 phosphorylation (Fig. 3B) and that luteolin and myricetin inhibited the AKT phosphorylation (Ser-473 and Ser 308) induced by LTA (Fig. 3C and D).

**Flavonoids inhibit LTA-induced increases in COX-2 transcription and translation**

Incubating HGFs with LTA significantly increased COX-2 transcription and translation. The increase in COX-2 transcription induced by LTA was markedly attenuated by treatment with the studied flavonoids. Treatment with luteolin caused a reduction in COX-2 transcription to below basal levels (Fig. 4A). Likewise, as shown in Fig. 4B, LTA stimulated COX-2 protein expression to a degree up to three times over the basal levels. Treatment with the flavonoids significantly attenuated LTA-mediated COX-2 expression.

Fig. 4. Flavonoids inhibit LTA effects on the transcription and translation of COX-2 in HGFs. A – Cells were pretreated with flavonoids (10 μM) for 30 min before being treated with LTA (10 μg/ml) for 4 h. Cellular lysates were processed by SDS-PAGE and membranes were blocked and incubated with antibodies that recognized COX-2. To confirm that the same protein concentration was used, the membranes were stripped and incubated with γ-tubulin. The results are representative of three separate experiments. SEMs were obtained by densitometry. *p < 0.05; significantly different from the values for cells treated with LTA only. B – Cells were treated with a flavonoid (10 μM) for 30 min and subsequently treated with LTA (10 μg/ml) for 4 h. Total RNA was extracted and COX-2 mRNA induction was determined using RT-PCR. Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) was used as a control. Densitometric analyses represent the means and SEMs of five separate experiments. *p < 0.05; significantly different from the values for cells treated with LTA only.
DISCUSSION

In this study, we examined the effects of four flavonoids (luteolin, fisetin, myricetin and morin) on the regulation of MAPK activity and LTA-induced COX-2 expression in HGFs. Our results showed that luteolin and myricetin inhibit ERK1/2, p38 and AKT phosphorylation in HGFs. We also found that myricetin blocks COX-2 expression.

LTA plays a key role in Gram-positive bacteria and induces various inflammatory mediators responsible for pathophysiological changes. In the periodontium, LTA promotes inhibition of cell growth and proliferation of epithelial cells in the gingival tissue [43], and induces higher levels of IL-1β than those induced by LPS [43]. LTA-induced iNOS expression, NO release in RAW 264.7 macrophages and LTA-stimulated ERK1/2 activation are mediated through the TLR2 receptor and involve MEK and PI3K activation and NF-κB activation [44]. Here, we found that LTA promotes the activation of ERK1/2 and p38 after 15 min of treatment with LTA (10 μg/ml). Kuo reported similar results [46]. Activation of p38 MAPK has been demonstrated to be involved in LTA-induced COX-2 expression and PGE2 release in human pulmonary epithelial cells [45]. Chiang et al. [46] found that LTA-induced COX-2 synthesis and PGE2 expression were mediated by the activation of PKC and ERK1/2 in macrophages. We previously reported that p38 is involved in COX-2 synthesis and PGE2 release in human gingival fibroblasts [48] and that prostaglandin production is involved in gingival inflammatory processes.

Inhibition of the inflammatory response induced by PAMPs is an attractive therapy target in the treatment of periodontal disease. Natural plant-derived products have been shown to inhibit the expression of the enzyme nitric oxide synthase [49] and to inhibit COX-2 expression in HGFs treated with lipopolysaccharide [3].

On the other hand, flavonoids have anti-inflammatory actions, so it is interesting to investigate the relationship between those actions and the regulation of LTA actions. Huang et al. [50] found that wogonin inhibits LTA-induced nitric oxide gene expression and nitric oxide production in macrophages. We found that luteolin inhibits nitric oxide expression induced by lipopolysaccharide.

Streptococcus sanguinis is a Gram-positive bacterial species that acts as a primary colonizer and promotes plaque aggregation. LTA is a structural component of the external wall and cytoplasmic membrane of Gram-positive bacteria. It is made up of glycerol phosphate polymers and repeating units esterified with D-alanine and α-D-N-acetylglucosamine. The D-alanine content is directly related to the inflammatory potential of LTA. Numerous recent articles have reported that LTA stimulates immune cells to synthesize TNF-α [51], IL-6 [52], IL-8 [53] and nitric oxide [50]. LTA associates with type 2 TLRs and activates kinases such as mitogen-activated protein kinase [54, 55] and AKT [52].

HGFs play an important role in the host defense mechanisms. They recognize and respond to various PAMPs by synthesizing and releasing mediators that
promote inflammatory responses, such as prostaglandins, IL-8, IL-1, IL-6 and TNF-α [50]. Activation of HGF by LTA promotes the secretion of IL-8, IL-1β and COX-2 [43].

Previous studies have shown that flavone derivatives inhibit the IL-1β synthesis induced by S. sanguinis-derived LTA in H9c2 mouse cardiomyocyte-derived cells [56]. Likewise, a number of studies have suggested that flavones can affect the production of inflammatory cytokines in activated cells. Treatment with luteolin or quercetagetin has been shown to inhibit the production of IL-1β in H9c2 cells and the activation of mitogen-activated proteins such as ERK1/2, JNK, p38 and AKT.

In conclusion, our experiments showed that flavonoids inhibit the effect of LTA on the activation of various kinases in HGFs. In particular, we found that myricetin inhibits LTA-induced COX-2 expression. These findings provide a good reason to continue studying the effects of flavonoids, especially myricetin, on inflammatory responses in the context of the development of periodontal disease.

Acknowledgments. This study was supported by Grants from Dirección General de Asuntos del Personal Académico [DGAPA] PAPIIT IN209412-3.

REFERENCES

1. Gutiérrez-Venegas, G. and Cardoso-Jiménez, P. Lipoteichoic acid promotes accumulation of β-catenin via AKT in human gingival fibroblasts. Int. Immunopharmacol. 11 (2011) 1278–1284.
2. Gutiérrez-Venegas, G., Contreras-Marmolejo, L.A., Román-Alvárez, P. and Barajas-Torres, C. Aggregatibacter actinomycetemcomitans lipopolysaccharide affects human gingival fibroblast cytoskeletal organization. Cell Biol. Int. 32 (2008) 417–426.
3. Gutiérrez-Venegas, G. and Contreras-Sánchez, A. Luteolin and fisetin inhibit the effects of lipopolysaccharide obtained from Porphyromonas gingivalis in human gingival fibroblasts. Mol. Biol. Rep. 40 (2013) 477–485.
4. Graves, D. Cytokines that promote periodontal tissue destruction. J. Periodontol. 79 (2008) 1585–1591.
5. Kinane, D.F. and Bartold, P. Clinical relevance of the host responses of periodontitis. Periodontal 2000 43 (2007) 278–293.
6. Takashiba, S., Takigawa, M., Takahashi, K., Myokai, F., Nishimura F., Chihatra, T., Kurihara, H., Nomura, Y and Murayama, Y. Interleukin-8 is a major neutrophil chemotactic factor derived from cultured human gingival fibroblasts stimulated with interleukin-1 beta or tumor necrosis factor alpha. Infect. Immun. 60 (1992) 5253–5258.
7. Hosokawa, Y., Hosokawa, I., Ozaki, K., Nakae, H. and Matsuo, T. Increase of CCL20 expression by human gingival fibroblasts upon stimulation with cytokines and bacterial endotoxin. Clin. Exp. Immunol. 142 (2005) 285–291.
8. Hosokawa, Y., Hosokawa, I., Ozaki, K., Nakae, H. and Matsuo, T. CXC chemokine ligand 16 in periodontal diseases: expression in diseased tissues and production by cytokine-stimulated human gingival fibroblasts. Clin. Exp. Immunol. 149 (2007) 146–154.
9. Hosokawa, I., Hosokawa, Y., Ozaki, K., Nakae, H. and Matsuo, T. Adrenomedullin suppresses tumour necrosis factor alpha-induced CXC chemokine ligand 10 production by human gingival fibroblasts. Clin. Exp. Immunol. 152 (2008) 568–575.
10. Hosokawa, Y., Hosokawa, I., Ozaki, K., Nakae, H. and Matsuo, T. CC chemokine ligand 17 in periodontal diseases: expression in diseased tissues and production by human gingival fibroblasts. J. Periodontal Res. 43 (2008) 471–477.
11. Hosokawa, Y., Hosokawa, I., Ozaki, K., Nakae, H. and Matsuo, T. Cytokines differentially regulate CXCL10 production by interferon-gamma-stimulated or tumor necrosis factor-alpha-stimulated human gingival fibroblasts. J. Periodontal Res. 44 (2009) 225–231.
12. O’Dell, D.S. and Ebersole, J.L. Avidity of antibody responses to Actinobacillus actinomycetemcomitans in periodontitis. Clin. Exp. Immunol. 101 (1995) 295–301.
13. Fletcher, J.M., Nair, S.P., Ward, J.M., Henderson, B. and Wilson, M. Analysis of the effect of changing environmental conditions on the expression patterns of exported surface-associated proteins of the oral pathogen Actinobacillus actinomycetemcomitans. Microb. Pathog. 30 (2001) 359–368.
14. Hajishengallis, G., Sojar, H., Genco, R.J. and DeNardin, E. Intracellular signaling and cytokine induction upon interactions of Porphyromonas gingivalis fimbriae with pattern-recognition receptors. Immunol. Invest. 33 (2004) 157–172.
15. Tietze, K., Dalpke, A., Morath, S., Mutters, R., Heeg, K. and Nonnenmacher, C. Differences in innate immune responses upon stimulation with Gram-positive and Gram-negative bacteria. J. Periodontal Res. 41 (2006) 447–454.
16. Hurttia, H.M., Pelto, L.M. and Leino, L. Evidence of an association between functional abnormalities and defective diacylglycerol kinase activity in peripheral blood neutrophils from patients with localized juvenile periodontitis. J. Periodontal Res. 32 (1997) 401–407.
17. Milward, M.R., Chapple, I.L., Wright, H.J., Millard, J.L., Matthews, J.B. and Cooper, P.R. Differential activation of NF-kappaB and gene expression in oral epithelial cells by periodontal pathogens. Clin. Exp. Immunol. 148 (2007) 307–324.
18. Yamaguchi, T., Nariushi, K., Arai, H., Nishimura, F. and Takashiba, S. IL-6/sIL-6R enhances cathepsin B and L production via caveolin-1-mediated JNK-AP-1 pathway in human gingival fibroblasts. J. Cell Physiol. 217 (2008) 423–432.
19. Guan, S.M., Zhang, M., He, J.J. and Wu, J.Z. Mitogen-activated protein kinases and phosphatidylinositol 3-kinase are involved in Prevotella intermedia-induced proinflammatory cytokines expression in human periodontal ligament cells. *Biochem. Biophys. Res. Commun.* 386 (2009) 471–476.
20. Arai, Y., Watanabe, S., Kimira, M., Shimo, K., Mochizuki, R. and Kinae, N. Dietary intakes of flavonols, flaocnes and isoflavones by Japanese women and the inverse correlation between quercetina intake and plasma LDL colesterol concentration. *J. Nutr.* 130 (2000) 2243–2250.
21. Maher, P., Dargusch, R., Ehren, J.L., Okada, S., Sharma, K. and Schubert, D. Fisetin powers methylglyoxal dependent protein glycation and limits the complications of diabetes. *PLoS ONE* 6 (2011) e21226.
22. Lee, S.E., Jeong, S.I., Yang, H., Park, C.S., Jin, Y.H. and Park, Y.S. Fisetin induces Nrf2-mediated HO-1 expression through PKC-d and p38 in human umbilical vein endotelial cells. *J. Cell Biochem.* 112 (2011) 2352–2360.
23. Khan, N, Asim, M., Afaq, E., Abu Zaid, M. and Mukhatai, H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic mude mice. *Cancer Res.* 68 (2008) 8555–8563.
24. Prasath, G.S. and Subramanian, S.P. Modulatory effects of fisetin a bioflavonoid on hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in hepatic and renal tissues in streptozotocin-induced diabetic rats. *Eur. J. Pharmacol.* 668 (2011) 492–496.
25. Maher, P. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. *Genes Nutr.* 4 (2009) 297–307.
26. Kitagawa, S., Sakamoto, H. and Tano, H. Inhibitory effects of flavonoids on free radical-induced hemolysis and their oxidative effects on hemoglobin a. *Chem. Pharm. Bull.* 52 (2004) 999–1001.
27. Wu, T.W, Zeng, L.H. and Wu, K.P. Fung. Morin hydrate is a plant-derived and antioxidant-based hepatoprotector. *Life Sci.* 53 (1993) PL213–PL218.
28. Galvez, J., Coelho, G., Crespo, M.E., Cruz, T., Rodriguez-Cabezas, M.E., Concha, A., González, M. and Zarzuelo, A. Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat. *Aliment Pharmacol. Ther.* 15 (2001) 2027–2039.
29. Lee, K.M., Kang, N.J., Han, J.H., Lee, K.W. and Lee, H.J. Myricetin down-regulates phorbol ester-induced cyclooxygenase-2 expression in mouse epidermal cells by blocking activation of nuclear factor kappa B. *J. Agric. Food Chem.* 55 (2007) 9678–9684.
30. Lee, K.W., Kang, N.J., Rogozin, E.A., Kim, H.G., Cho, Y.Y., Bode, A.M., Lee, H.J., Surh, Y.J., Bowden, G.T. and Dong, Z. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. *Carcinogenesis* 28 (2007) 1918–1927.
31. Kumamoto, T., Fuji, M. and Hou, D.X. Myricetin directly targets JAK1 to inhibit cell transformation. *Cancer Lett.* 275 (2009) 17–26.
32. Kumamoto, T., Fujii, M. and Hou, D.X. AKT is a direct target for myricetin to inhibit cell transformation. Mol. Cell Biochem. 332 (2009) 33–41.

33. Kim, J.E, Kwon, J.Y., Lee, D.E., Kang, N.J., Heo, Y.S., Lee, K.W. and Lee, H.J. MKK4 is a novel target for the inhibition of tumor necrosis factor alpha-induced vascular endothelial growth factor expression by myricetin. Biochem. Pharmacol. 77 (2009) 412–421.

34. Jung, S.K, Lee, K.W., Byun, S., Kang, N.J., Lim, S.H., Heo, Y.S., Bode, A.M., Bowde, G.T., Lee H.J. and Dong, Z. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res. 68 (2008) 6021–6029.

35. Qian, L.B., Wang, H.P., Chen, Y., Chen, F.X., Ma, Y.Y., Bruce, I.C. and Xia, Q. Luteolin reduces high glucose-mediated impairment of endothelium-dependent relaxation in rat aorta by reducing oxidative stress. Pharmacol. Res. 61 (2006) 281–287.

36. Horinaka, M., Yoshida, T., Shiraiishi, T., Nakata, S., Wakada, M., Nakanishi, R., Nishino, H., Matsui, H. and Sakai, T. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24 (2005) 7180–7189.

37. Ueda, H., Yamazaki, C. and Yamazaki, M. Inhibitory effect of Perilla leaf extract and luteolin on mouse skin tumor promotion. Biol. Pharm. Bull. 26 (2003) 560–563.

38. Ueda, H., Yamazaki, C. and Yamazaki, M. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol. Pharm. Bull. 25 (2002) 1197–1202.

39. Ueda, H., Yamazaki, C. and Yamazaki, M. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol. Pharm. Bull. 25 (2002) 1197–1202.

40. Gutiérrez-Venegas, G., Kawasaki-Cárdenas, P., Arroyo-Cruz, S.R. and Maldonado-Frias, S. Luteolin inhibits lipopolysaccharide actions on human gingival fibroblasts. Eur. J. Pharmacol. 10 (2006) 95–105.

41. Chomczynski, P. and Sachii, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-cloroform extraction. Anal. Biochem. 162 (1987) 156–159.

42. Fort, P., Marty, L., Piechaczyk, M., el Sabrouty, S., Dani, C., Jeanteur, P. and Blanchard, J.M. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-2-phosphate-dehydrogenase multigenic family. Nucleic Acids Res. 13 (1985) 1431–1442.

43. Uehara, A., Sugawara, S., Tamai, R. and Takada, H. Contrasting responses of human gingival and colonic epithelial cells to lipopolysaccharides, lipoteichoic acids and peptidoglycans in the presence of soluble CD14. Med. Microbiol. Immunol. 189 (2001) 185–192.

44. Pöllänen, M.T., Salonen, J.I., Grenier, D. and Uitto, V.J. Epithelial cell response to challenge of bacterial lipoteichoic acids and lipopolysaccharides in vitro. J. Med. Microbiol. 49 (2000) 245–252.
45. Liljeroos, M., Vuolteenaho, R., Morath, S., Hartung, T., Hallman, M. and Ojaniemi, M. Bruton’s tyrosine kinase together with PI 3-kinase are part of Toll-like receptor 2 multiprotein complex and mediate LTA induced Toll-like receptor 2 responses in macrophages. *Cell Signal.* 19 (2007) 625–633.

46. Lin, C.H., Kuan, I.H., Wang, C.H., Lee, H.M., Lee, W.S., Sheu, J.R., Hsiao, G., Wu, C.H. and Kuo, H.P. Lipoteichoic acid-induced cyclooxygenase-2 expression requires activations of p44/42 and p38 mitogen-activated protein kinase signal pathways. *Eur. J. Pharmacol.* 450 (2002) 1–9.

47. Chiang, L.L., Kuo, C.T., Wang, C.H., Chen, T.F., Ho, Y.S., Kuo, H.P. and Lin, C.H. Involvement of nuclear factor-kappaB in lipoteichoic acid-induced cyclooxygenase-2 expression in RAW 264.7 macrophages. *J. Pharm. Pharmacol.* 55 (2003) 115–123.

48. Gutiérrez-Venegas, G., Maldonado-Frías, S., Ontiveros-Granados, A. and Kawasaki-Cárdenas, P. Role of p38 in nitric oxide synthase and cyclooxygenase expression and nitric oxide and PGE2 synthesis in human gingival fibroblasts stimulated with lipopolysaccharides. *Life Sci.* 77 (2005) 60–73.

49. Takahama, U., Yamamoto, A., Hirota, S. and Oniki, T. Quercetin-dependent reduction of salivary nitrite to nitric oxide under acidic conditions and interaction between quercetin and ascorbic acid during the reduction. *J. Agric. Food Chem.* 51 (2003) 6014–6020.

50. Huang, G.C., Chow, J.M., Shen, S.C., Yang, L.Y., Lin, C.W. and Chen, Y.C. Wogonin but not Nor-wogonin inhibits lipopolysaccharide and lipoteichoic acid-induced iNOS gene expression and NO production in macrophages. *Int. Immunopharmacol.* 7 (2007) 1054–1063.

51. Chapecar, M.S., Zaremba, T.G., Kuester, R.K. and Hitchins, V.M. Synergistic induction of tumor necrosis factor alpha by bacterial lipopolysaccharide and lipoteichoic acid in combination with polytetrafluoroethylene particles in a murine macrophage cell line RAW 264.7. *J. Biomed. Mater. Res.* 31 (1996) 251–256.

52. Dahle, M.K., Øverland, G., Myhre, A.E., Stuestøl, J.F., Hartung, T., Krohn, C.D., Mathiesen, Ø., Wang, J.E. and Aasen, A.O. The phosphatidylinositol 3-kinase/protein kinase B signaling pathway is activated by lipoteichoic acid and plays a role in Kupffer cell production of interleukin-6 (IL-6) and IL-10. *Infect. Immun.* 72 (2004) 5704–5711.

53. Bruserud, Ø., Wendelbo, Ø. and Paulsen, K. Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts. *Eur. J. Haematol.* 73 (2004) 340–350.

54. Lonchampt, M.O., Auguet, M., Delaflotte, S., Goulin-Schulz, J., Chabrier, P.E. and Braquet, P. Lipoteichoic acid: a new inducer of nitric oxide synthase. *J. Cardiovasc. Pharmacol.* 1 (1992) 20 Suppl 12, S145–147.

55. Chang, Y.C., Li, P.C., Chen, B.C., Chang, M.S., Wang, J.L., Chiu, W.T. and Lin, C.H. Lipoteichoic acid-induced nitric oxide synthase expression in
RAW 264.7 macrophages is mediated by cyclooxygenase-2, prostaglandin E2, protein kinase A, p38 MAPK and nuclear factor-kappaB pathways. Cell Signal. 18 (2006) 1235–1243.

56. Gutiérrez-Venegas, G. and Bando-Campos, C.G. The flavonoids luteolin and quercetagetin inhibit lipoteichoic acid actions on H9c2 cardiomyocytes. Int. Immunopharmacol. 10 (2010) 1003–1009.